Hu-Ting Tang1, Wei-Hao Mu1, Yu-Jing Xiang1, Yong An1. 1. Department of Cardiovascular and Thoracic Surgery, Children's Hospital of Chongqing Medical University/National Clinical Research Center for Child Health and Disorders/Ministry of Education Key Laboratory of Child Development and Disorders/Chongqing Key Laboratory of Pediatrics, Chongqing 400014, China.
Abstract
OBJECTIVES: To study the association between hepatocyte growth factor (HGF) and treatment response in mice with hypoxic pulmonary arterial hypertension (HPAH) and the possibility of HGF as a new targeted drug for HPAH. METHODS: After successful modeling, the HPAH model mice were randomly divided into two groups: HPAH group and HGF treatment group (tail vein injection of recombinant mouse HGF 1 mg/kg), with 10 mice in each group. Ten normal mice were used as the control group. After 5 weeks, echocardiography was used to measure tricuspid peak velocity, right ventricular systolic pressure, right ventricular hypertrophy index, and right ventricular/body weight ratio; the Griess method was used to measure the content of nitric oxide in serum; ELISA was used to measure the serum level of endothelin-1; transmission electron microscopy was used to observe changes in the ultrastructure of pulmonary artery. RESULTS: Compared with the HGF treatment and normal control groups, the HPAH group had significantly higher tricuspid peak velocity, right ventricular systolic pressure, right ventricular hypertrophy index, and right ventricular/body weight ratio (P<0.05). The transmission electron microscopy showed that the HPAH group had massive destruction of vascular endothelial cells and disordered arrangement of the elastic membrane of arteriolar intima with rupture and loss. The structure of vascular endothelial cells was almost complete and the structure of arterial intima elastic membrane was almost normal in the HGF treatment group. Compared with the normal control and HGF treatment groups, the HPAH group had significantly higher serum levels of nitric oxide and endothelin-1 (P<0.05). CONCLUSIONS: Increasing serum HGF level can alleviate the impact of HPAH on the cardiovascular system of mice, possibly by repairing endothelial cell injury, improving vascular remodeling, and restoring the normal vasomotor function of pulmonary vessels.
OBJECTIVES: To study the association between hepatocyte growth factor (HGF) and treatment response in mice with hypoxic pulmonary arterial hypertension (HPAH) and the possibility of HGF as a new targeted drug for HPAH. METHODS: After successful modeling, the HPAH model mice were randomly divided into two groups: HPAH group and HGF treatment group (tail vein injection of recombinant mouse HGF 1 mg/kg), with 10 mice in each group. Ten normal mice were used as the control group. After 5 weeks, echocardiography was used to measure tricuspid peak velocity, right ventricular systolic pressure, right ventricular hypertrophy index, and right ventricular/body weight ratio; the Griess method was used to measure the content of nitric oxide in serum; ELISA was used to measure the serum level of endothelin-1; transmission electron microscopy was used to observe changes in the ultrastructure of pulmonary artery. RESULTS: Compared with the HGF treatment and normal control groups, the HPAH group had significantly higher tricuspid peak velocity, right ventricular systolic pressure, right ventricular hypertrophy index, and right ventricular/body weight ratio (P<0.05). The transmission electron microscopy showed that the HPAH group had massive destruction of vascular endothelial cells and disordered arrangement of the elastic membrane of arteriolar intima with rupture and loss. The structure of vascular endothelial cells was almost complete and the structure of arterial intima elastic membrane was almost normal in the HGF treatment group. Compared with the normal control and HGF treatment groups, the HPAH group had significantly higher serum levels of nitric oxide and endothelin-1 (P<0.05). CONCLUSIONS: Increasing serum HGF level can alleviate the impact of HPAH on the cardiovascular system of mice, possibly by repairing endothelial cell injury, improving vascular remodeling, and restoring the normal vasomotor function of pulmonary vessels.
Authors: Toshie Saito; Kazuya Miyagawa; Shih-Yu Chen; Rasa Tamosiuniene; Lingli Wang; Orr Sharpe; Erik Samayoa; Daisuke Harada; Jan-Renier A J Moonen; Aiqin Cao; Pin-I Chen; Jan K Hennigs; Mingxia Gu; Caiyun G Li; Ryan D Leib; Dan Li; Christopher M Adams; Patricia A Del Rosario; Matthew Bill; Francois Haddad; Jose G Montoya; William H Robinson; Wendy J Fantl; Garry P Nolan; Roham T Zamanian; Mark R Nicolls; Charles Y Chiu; Maria E Ariza; Marlene Rabinovitch Journal: Circulation Date: 2017-09-21 Impact factor: 29.690
Authors: Ravindra K Sharma; Aline C Oliveira; Tao Yang; Marianthi M Karas; Jing Li; Gilberto O Lobaton; Victor P Aquino; Iñaki Robles-Vera; Annette D de Kloet; Eric G Krause; Andrew J Bryant; Amrisha Verma; Qiuhong Li; Elaine M Richards; Mohan K Raizada Journal: Hypertension Date: 2020-05-18 Impact factor: 10.190
Authors: Alexandre G Oliveira; Tiago G Araújo; Bruno de Melo Carvalho; Guilherme Z Rocha; Andrey Santos; Mario J A Saad Journal: Front Endocrinol (Lausanne) Date: 2018-08-30 Impact factor: 5.555